单核细胞与淋巴细胞比值(MLR)和c反应蛋白(CRP)作为不同肺部疾病,特别是SCLC的诊断生物标志物的评价

Yue Zhang, Zhigang Xin, Qun Zhang, Zhijun Zhang, Xiao-yuan Feng
{"title":"单核细胞与淋巴细胞比值(MLR)和c反应蛋白(CRP)作为不同肺部疾病,特别是SCLC的诊断生物标志物的评价","authors":"Yue Zhang, Zhigang Xin, Qun Zhang, Zhijun Zhang, Xiao-yuan Feng","doi":"10.1515/tjb-2022-0282","DOIUrl":null,"url":null,"abstract":"Abstract Objectives This study aims to assess the capability of monocyte-to-lymphocyte ratio (MLR) and C-reactive protein (CRP) to diagnose and differentiate diagnosis various types of lung diseases, including non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC) and benign pulmonary diseases (BPD). Methods Patients diagnosed with lung cancer and BPD by pathology and healthy volunteers were enrolled. Laboratory test data and clinical pathologic characteristics were recorded, including complete blood counts, CRP, NSE, CYFRA21-1 levels, age, gender, and histological type. The differences between the groups were calculated and compared. Receiver operating characteristic (ROC) analysis was performed to specify the diagnostic value of MLR and CRP in NSCLC, SCLC, and BPD. Results 2042 patients and 996 healthy volunteers were involved (NSCLC, SCLC, and BPD patients were 1,245, 302, and 495, respectively). Compared to healthy volunteers, MLR and CRP in patients with NSCLC, SCLC, and BPD were significantly higher (p<0.0001). The areas under the curve (AUC) were 0.703, 0.828, 0.784, 0.703, 0.813, and 0.798, respectively. Through the combined analysis of MLR and CRP, the AUC could be improved to 0.765, 0.882, and 0.843, respectively. Additionally, an evaluation of the diagnostic value of MLR+CRP+ NSE+CYFRA21-1 gave the AUC of 0.898 (95 % CI:0.882–0.914), 0.986 (95 % CI:0.975–0.996) and 0.925 (95 % CI:0.906–0.945), respectively. Moreover, MLR and CRP could differentiate early-stage patients (0 and I stages) from late-stage (IV stage) for NSCLC and SCLC patients, with p-values of less than 0.0001, respectively. Conclusions MLR and CRP could be good diagnostic indicators of lung diseases, especially for SCLC and BPD. Both could improve the diagnostic efficiency of traditional lung cancer biomarkers, demonstrating excellent diagnostic value, particularly in SCLC. This may supply early treatment and survival advantages for patients.","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"48 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the monocyte-to-lymphocyte ratio (MLR) and c-reactive protein (CRP) as diagnostic biomarkers in different lung diseases, especially for SCLC\",\"authors\":\"Yue Zhang, Zhigang Xin, Qun Zhang, Zhijun Zhang, Xiao-yuan Feng\",\"doi\":\"10.1515/tjb-2022-0282\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Objectives This study aims to assess the capability of monocyte-to-lymphocyte ratio (MLR) and C-reactive protein (CRP) to diagnose and differentiate diagnosis various types of lung diseases, including non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC) and benign pulmonary diseases (BPD). Methods Patients diagnosed with lung cancer and BPD by pathology and healthy volunteers were enrolled. Laboratory test data and clinical pathologic characteristics were recorded, including complete blood counts, CRP, NSE, CYFRA21-1 levels, age, gender, and histological type. The differences between the groups were calculated and compared. Receiver operating characteristic (ROC) analysis was performed to specify the diagnostic value of MLR and CRP in NSCLC, SCLC, and BPD. Results 2042 patients and 996 healthy volunteers were involved (NSCLC, SCLC, and BPD patients were 1,245, 302, and 495, respectively). Compared to healthy volunteers, MLR and CRP in patients with NSCLC, SCLC, and BPD were significantly higher (p<0.0001). The areas under the curve (AUC) were 0.703, 0.828, 0.784, 0.703, 0.813, and 0.798, respectively. Through the combined analysis of MLR and CRP, the AUC could be improved to 0.765, 0.882, and 0.843, respectively. Additionally, an evaluation of the diagnostic value of MLR+CRP+ NSE+CYFRA21-1 gave the AUC of 0.898 (95 % CI:0.882–0.914), 0.986 (95 % CI:0.975–0.996) and 0.925 (95 % CI:0.906–0.945), respectively. Moreover, MLR and CRP could differentiate early-stage patients (0 and I stages) from late-stage (IV stage) for NSCLC and SCLC patients, with p-values of less than 0.0001, respectively. Conclusions MLR and CRP could be good diagnostic indicators of lung diseases, especially for SCLC and BPD. Both could improve the diagnostic efficiency of traditional lung cancer biomarkers, demonstrating excellent diagnostic value, particularly in SCLC. This may supply early treatment and survival advantages for patients.\",\"PeriodicalId\":23344,\"journal\":{\"name\":\"Turkish Journal of Biochemistry\",\"volume\":\"48 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turkish Journal of Biochemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/tjb-2022-0282\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Biochemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/tjb-2022-0282","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

摘要目的探讨单核细胞与淋巴细胞比值(MLR)和c反应蛋白(CRP)对非小细胞肺癌(NSCLC)、小细胞肺癌(SCLC)和良性肺疾病(BPD)等多种肺部疾病的诊断和鉴别诊断能力。方法选择经病理诊断为肺癌和BPD的患者和健康志愿者。记录实验室检查资料和临床病理特征,包括全血细胞计数、CRP、NSE、CYFRA21-1水平、年龄、性别、组织学类型。计算并比较两组间的差异。采用受试者工作特征(ROC)分析,明确MLR和CRP在NSCLC、SCLC和BPD中的诊断价值。结果共纳入2042例患者和996名健康志愿者(NSCLC、SCLC和BPD患者分别为1245例、302例和495例)。与健康志愿者相比,NSCLC、SCLC和BPD患者的MLR和CRP显著升高(p<0.0001)。曲线下面积(AUC)分别为0.703、0.828、0.784、0.703、0.813和0.798。通过MLR和CRP的联合分析,AUC分别提高到0.765、0.882和0.843。此外,评估MLR+CRP+ NSE+CYFRA21-1的诊断价值,AUC分别为0.898(95 % CI: 0.882-0.914)、0.986(95 % CI: 0.975-0.996)和0.925(95 % CI: 0.906-0.945)。此外,MLR和CRP可以区分NSCLC和SCLC患者的早期(0期和I期)和晚期(IV期),p值分别小于0.0001。结论MLR和CRP可作为肺部疾病的良好诊断指标,尤其对SCLC和BPD有较好的诊断价值。两者均能提高传统肺癌生物标志物的诊断效率,表现出优异的诊断价值,尤其是对SCLC的诊断价值。这可能为患者提供早期治疗和生存优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evaluation of the monocyte-to-lymphocyte ratio (MLR) and c-reactive protein (CRP) as diagnostic biomarkers in different lung diseases, especially for SCLC
Abstract Objectives This study aims to assess the capability of monocyte-to-lymphocyte ratio (MLR) and C-reactive protein (CRP) to diagnose and differentiate diagnosis various types of lung diseases, including non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC) and benign pulmonary diseases (BPD). Methods Patients diagnosed with lung cancer and BPD by pathology and healthy volunteers were enrolled. Laboratory test data and clinical pathologic characteristics were recorded, including complete blood counts, CRP, NSE, CYFRA21-1 levels, age, gender, and histological type. The differences between the groups were calculated and compared. Receiver operating characteristic (ROC) analysis was performed to specify the diagnostic value of MLR and CRP in NSCLC, SCLC, and BPD. Results 2042 patients and 996 healthy volunteers were involved (NSCLC, SCLC, and BPD patients were 1,245, 302, and 495, respectively). Compared to healthy volunteers, MLR and CRP in patients with NSCLC, SCLC, and BPD were significantly higher (p<0.0001). The areas under the curve (AUC) were 0.703, 0.828, 0.784, 0.703, 0.813, and 0.798, respectively. Through the combined analysis of MLR and CRP, the AUC could be improved to 0.765, 0.882, and 0.843, respectively. Additionally, an evaluation of the diagnostic value of MLR+CRP+ NSE+CYFRA21-1 gave the AUC of 0.898 (95 % CI:0.882–0.914), 0.986 (95 % CI:0.975–0.996) and 0.925 (95 % CI:0.906–0.945), respectively. Moreover, MLR and CRP could differentiate early-stage patients (0 and I stages) from late-stage (IV stage) for NSCLC and SCLC patients, with p-values of less than 0.0001, respectively. Conclusions MLR and CRP could be good diagnostic indicators of lung diseases, especially for SCLC and BPD. Both could improve the diagnostic efficiency of traditional lung cancer biomarkers, demonstrating excellent diagnostic value, particularly in SCLC. This may supply early treatment and survival advantages for patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
CXCL12/CXCR4 as a potential axis in diagnosis and predicting disease severity in COVID-19 patients: a new perspective Human estrogen receptor alpha (ERα) targeted cyclic peptides inhibit cell growth and induce apoptosis in MCF-7 cells In vitro and in silico investigations of the pro-apoptotic activity of Opuntia ficus-indica cladode extracts against K562 cells Evaluation of the implementation of the rational use of laboratory tests in the clinical chemistry laboratory Right vagotomy alters heart rate variability temporarily and increases total choline levels in rats
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1